2019
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer
Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer. Breast Cancer Research And Treatment 2019, 176: 445-451. PMID: 31028607, PMCID: PMC6556129, DOI: 10.1007/s10549-019-05248-2.Peer-Reviewed Original ResearchConceptsPatient-level analysisOncotype DXBreast cancerMedical oncologistsEarly-stage breast cancerGenomic testingPhysician networksODX testingMore patientsRetrospective studySEER-MedicareStudy criteriaSuboptimal treatmentCancer patientsMedian numberModifiable driversModifiable meansPatientsOncologistsLogistic mixed modelsEarly adoption periodWomenCancerPhysiciansGenomic assays
2016
Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.Peer-Reviewed Original ResearchHigh-risk diseaseOncotype DXRisk diseaseChemotherapy costsODX testingBreast cancerAdjuvant chemotherapyRisk womenPatient outcomesEnd Results-Medicare dataEarly-stage breast cancerER-positive breast cancerReal-world clinical practiceIntermediate-risk womenSEER-Medicare populationLow-risk diseaseHigh-risk womenPositive breast cancerWorld clinical practiceActual patient outcomesTotal Medicare paymentsNCCN guidelinesOverall cohortMultivariable analysisPathologic features
2015
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal Of Clinical Oncology 2015, 34: 130-138. PMID: 26598755, PMCID: PMC4872005, DOI: 10.1200/jco.2015.63.2489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlack or African AmericanBreast NeoplasmsClinical Trials, Phase II as TopicConfounding Factors, EpidemiologicErbB ReceptorsFemaleGene Expression ProfilingHealthcare DisparitiesHumansInsurance CoverageLymphatic MetastasisMiddle AgedMolecular Targeted TherapyNeoplasm StagingNorth CarolinaPoisson DistributionPractice Guidelines as TopicPrecision MedicinePredictive Value of TestsResearch DesignRisk AssessmentRisk FactorsConceptsNode-positive breast cancerNon-black womenODX testingNode-negative patientsBreast cancerOncotype DXBlack patientsRacial disparitiesEarly-stage breast cancerCarolina Breast Cancer StudyGuideline-concordant careNode-positive patientsCancer care qualityPopulation-based studyOncotype DX testingQuality of careNorth Carolina womenLow socioeconomic statusMedium tumor sizeBlack womenBreast Cancer StudyAdjuvant chemotherapyMore comorbiditiesConcordant careTumor sizeRacial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research And Treatment 2015, 153: 191-200. PMID: 26216535, PMCID: PMC4562432, DOI: 10.1007/s10549-015-3518-9.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy initiationChemotherapy initiationRisk scoreODX testingCarolina Breast Cancer StudyIntermediate-risk groupRacial variationBreast cancer patientsPopulation-based studyHigh-risk groupLarger tumor sizeLow-risk groupOncotype DX testingRacial differencesNorth Carolina womenBreast Cancer StudyAdjuvant chemotherapyTumor sizeCancer patientsRelative riskRisk groupsBreast cancerPoisson regressionYounger agePhase III
2014
Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.Peer-Reviewed Original ResearchReceipt of chemotherapyChemotherapy utilizationOncotype DXRisk diseaseBreast cancerODX testingEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerER-positive breast cancerIntermediate-risk diseaseHigh-risk patientsHigh-risk diseasePositive breast cancerBreast cancer populationAdjuvant chemotherapyNCCN guidelinesRisk patientsPathologic featuresRandomized trialsStudy criteriaCancer populationObservational studyRetrospective analysis